Rationale: Understanding the mechanisms of enzalutamide as an androgen receptor inhibitor in early prostate cancer could lead to improved patient selection for treatment. Objective: To study the effects of enzalutamide on surgical margin status and AR / DNA interaction and gene expression. Intervention : Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Effects of enzalutamide on tumor downstaging
Timeframe: From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months).
Genetic and transcriptional changes caused by enzalutamide
Timeframe: From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months).